Key Takeaways
- Sequential recovery underway, but margins still hurting: Revenue grew 19% YoY to ~₹559 crores as Crop Protection rebounded, yet EBITDA fell to ₹70 crores from ₹91 crores YoY, crushed by input costs.
- The margin recovery bet is back-end loaded: Management expects raw material softening to lift margins through H2, but the full return to pre-2022 levels is pushed to Q1/Q2 FY24, a timeline that depends on the trend holding.
- A structural shift toward CDMO is accelerating: The pharma business is pivoting to a hybrid model, with CDMO expected to become a "large part" of the segment next year, supported by a robust inquiry pipeline and new animal health capacity.
- Capex cycle is peaking, with revenue to follow later: Two major assets, a fungicide plant and an animal health facility, will be commissioned over the next two quarters, but meaningful commercial revenue from animal health won't start until FY25 after validation and approvals.
- What to watch next quarter: Whether the raw material softening actually converts to margin expansion in Q3, the pace of CDMO customer conversions from inquiries to contracts, and any update on the NGT joint committee report response due in January.
Margin Walk: The Input Cost Shock & Recovery Path
- The squeeze: EBITDA margin compressed sharply as a surge in raw material, utility, energy, and solvent prices, amplified by crude-driven freight inflation, could not be fully passed on. Pharma EBIT margin collapsed to 3%, with H1 EBIT at just ₹2 crores.
- Pharma's pass-through asymmetry: In APIs, market conditions, competition, and price erosion in the US and other regulated markets blocked cost pass-through. In CDMO, a more transparent cost model allowed pass-through, but with a lag of 6 to 9 months, sometimes a year.
- The recovery thesis: Key raw material prices have started softening, and if the trend continues, management expects sequential margin improvement in Q3 and Q4, with a return to mid-teen pharma EBIT margins by Q1/Q2 FY24.
- Cost levers in play: Business excellence initiatives and cost improvement programs have partly absorbed the input price impact, while strategic vendor development aims to de-risk the China supply chain and backward integrate for raw materials.
Manoj Mehrotra: "It's a little uncertain at this stage. We'll definitely see improvement in Q3 and Q4 because the raw material prices have softened. And if the same trend continues, I'll say, if I take a guess three quarters, it will be back to where we were."
Segment Performance
| Segment | Revenue (Q2 FY23) | YoY Growth | EBIT Margin | Commentary |
|---|---|---|---|---|
| Crop Protection | ₹269 crores | ▲ 42% | 13.1% | Strong demand for own products domestically and higher forecast from global innovators; plants at full capacity with ~10% spare capacity and debottlenecking underway. |
| Pharma | ₹290 crores | ▲ 4% | 3.0% | Subdued growth from temporary demand softening for key products; API volumes healthy but CDMO volumes hit by customer inventory correction, expected to normalize from Q1 2023. |
- Volume story: Overall Q2 volume grew 12% YoY, while H1 volume was slightly negative due to the Q1 shutdown at the crop site.
- Crop protection margin outlook: Management expects sequential quarter-on-quarter improvement and roughly 100 bps YoY improvement.
The CDMO Pivot & Pharma Pipeline
- The strategic shift: Management is explicitly steering the pharma business toward a hybrid model, targeting a 50-50 CDMO-to-API split initially, moving to 60-40 in favor of CDMO over time. The CDMO business is receiving increased inquiries from existing and new customers, with a robust future pipeline.
- API expansion continues alongside: New customers were added in the Middle East and Latin America, and new product launches in the anti-diabetic therapeutic area are gaining global traction. Over 10 products are in the development pipeline, with 3 to 4 planned for launch in FY23.
- DMF filing momentum: One DMF (Desvenlafaxine) was filed this year, with three more to be filed in the next four months. DMFs for Apixaban, Lacosamide, Dapagliflozin, and Empagliflozin are filed, with commercialization timed to patent expiries.
- CDMO revenue visibility is limited: Management declined to disclose how many CDMO products are launching in FY23 or FY24, citing customer confidentiality, and would only say the pipeline is strong. At least 2 to 3 products are planned during FY24, dependent on customer launch strategy.
Sameer Hiremath: "Next year itself will be large part of our business will shift on the pharma side towards the CDMO."
Capex Cycle: New Assets, Delayed Revenue
- Two major projects nearing completion: A new fungicide plant is planned for commissioning in Q4 FY23, with revenue accrual to start subsequently. A dedicated multipurpose Animal Health manufacturing facility is under construction and expected on stream by Q1 FY24.
- Animal Health revenue will lag commissioning: The first year after commissioning will be consumed by DMF filings and validation batches. Commercial supply starts only from year two onward, as different global markets open up and approvals are received.
- Targeted asset returns: Management is working toward a 1.5x asset turnover ratio for the Animal Health plant, with EBITDA margins well over 20%, in excess of pre-September 2021 levels. New capex across crop protection and animal health is expected to reach peak asset turns of 1.4 to 1.5x within 24 to 30 months.
- CWIP build-up: Capital work in progress is expected to reach ₹150 to 160 crores by end of March, covering both the fungicide project and the Animal Health facility. Management declined to provide a project-wise breakup.
- Funding in place: IFC has approved a $50 million loan, which the company is withdrawing in phases.
Sameer Hiremath: "With an EBITDA margin that in excess of what we have historically pre September '21 numbers, well over 20% EBITDA margins."
NGT Liability: A Contained Risk
- The trigger: A National Green Tribunal joint committee report was released on 19th October, and Hikal has been given time until January 2023 to file its response.
- Management's risk assessment: The company views the probability of being asked to pay any significant amount as "extremely low," citing a historical pattern where NGT recommendations for chemical industry incidents have resulted in stays by the Supreme Court, and where any amounts ultimately paid have been "very nominal."
Sameer Hiremath: "Even if we have to, the chances of us to ask to pay the entire amount is extremely low. There are several recourses and things we see of NGT recommendation made in the past for all chemical incidences in the past have resulted in stay by the Supreme Court. And even any amounts have to be paid, there's a very nominal amount."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Full-year revenue | Confident of beating overall FY22 revenues | FY23 |
| Quarterly revenue run rate | Maintain ~₹550 crores and do slightly better quarter-on-quarter | Q3 and Q4 FY23 |
| Margin recovery | Return to September/December 2021 margin levels | Q1 to Q2 FY24 |
| Pharma EBIT margin | Revert to mid-teen margins, provided raw material softening continues | Q1/Q2 FY24 |
| Fungicide plant commissioning | Plant commissioned, revenue accrual begins subsequently | Q4 FY23 |
| Animal Health facility | Multipurpose manufacturing facility on stream | Q1 FY24 |
| Animal Health commercialization | Commercial supply starts after DMF filings, validation, and approvals | FY25 onwards |
| CDMO product launches | At least 2 to 3 products planned, dependent on customer launch strategy | FY24 |
| New capex asset turns | Peak asset turnover of 1.4 to 1.5x reached | 24 to 30 months from commissioning |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Revenue | ₹559 cr, +19% YoY from ₹469 cr in Q2 FY22 |
| H1 FY23 revenue | ₹938 cr, flat YoY |
| EBITDA | ₹70 cr, vs ₹91 cr in Q2 FY22 |
| H1 FY23 EBITDA | ₹92 cr |
| PAT | ₹25 cr, vs ₹44 cr in Q2 FY22 and loss of ₹9 cr in Q1 FY23 |
| Crop Protection revenue | ₹269 cr, +42% YoY from ₹190 cr in Q2 FY22 |
| Crop Protection EBIT margin | 13.1%, EBIT of ₹35.3 cr |
| Pharma revenue | ₹290 cr, +4% YoY from ₹280 cr in Q2 FY22 |
| Pharma EBIT margin | 3%, EBIT of ₹10.6 cr |
| Volume growth | 12% YoY; H1 volume growth slightly negative |
| Crop capacity utilization | ~90%, with ~10% spare capacity available |
| Net debt | ₹742 cr, up marginally from ₹690 cr in Q1 FY23 |
| CWIP | ₹309 cr, largely for crop plant commissioning in Q4 FY23 |
| Credit rating | A+ by ICRA, long-term |